menu
    • menu
    [{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Albion","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Albion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albion \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Albion \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Bayer AG"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Bayer AG"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferrous Bisglycinate

    Menu

    Ferrous Bisglycinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lupin Ltd

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol,Ferrous Bisglycinate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lupin Launches Minzoya in the US for Contraceptive Use

                            Details : Minzoya (levonorgestrel and ethinyl estradiol and ferrous bisglycinate Tablets) received approval from the US FDA, it is indicated for use by females of reproductive potential to prevent pregnancy.

                            Product Name : Minzoya

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol,Ferrous Bisglycinate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            16 Weeks' Dietary Supplementation With Iron and Iron + Vitamin C on Cerebral Blood Flow and Energy Expenditure...

                            Details : Iron Bis-Glycinate Chelate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cerebral Blood Flow.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 20, 2020

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Evaluation of 16 Weeks' Dietary Supplementation With Iron Bis-glycinate Plus Vitamin C on Cognitive F...

                            Details : Iron Bis-Glycinate Chelate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Albion

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Albion

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous ...

                            Details : Ferrochel is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2014

                            Lead Product(s) : Ferrous Bisglycinate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth